
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is forecasting substantial earnings growth, with anticipated GAAP earnings of $4.73 per diluted share for 2025 and $5.17 per diluted share for 2026, reflecting increased confidence in the Human Nutrition and Health segment's strength. The company has demonstrated operational efficiency and revenue growth, reporting a revenue increase of 9.8% year-over-year, alongside improving gross and net margins, which rose to 35.6%. Furthermore, with the potential to become debt-free by the end of the year and the ability to pursue accretive M&A transactions, Balchem's strong balance sheet supports a positive financial outlook.
Bears say
Balchem Corp's financial outlook has been downgraded, with projected earnings for full-year 2026 revised down to $5.10 per diluted share from a previous estimate of $5.17, contributing to a decline in the price-to-earnings (P/E) multiple from 39.6x to 37.9x. The company is facing significant risks, including slower growth in its core businesses, inflationary pressures, and potential setbacks related to new product launches and regulatory approvals from partners. Additionally, revenue performance has lagged, as evidenced by the Human Nutrition and Health segment reporting revenue of $166.1 million in 4Q25, falling short of the forecasted $170 million, indicating potential ongoing challenges in meeting market expectations.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares